BioInformant is honored to be a sponsor for the upcoming “Biorepositories and Sample Management Summit” in Boston, Massachussetts, over October 12-14, 2015. This 3-day event promises to be the most interactive biobanking community event of the year.
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Market Penetration for Cord Tissue Storage in the U.S.
While the cord blood banking industry emerged in the late 1980’s and early 1990’s, the cord tissue storage industry didn’t emerge until much later when a Taiwanese company launched the service in 2008 (Healthbank Biotech). By 2009, two companies in Hong Kong were offering the service of cord tissue storage. It took until 2010 for the first U.S. cord blood bank, Cord Blood Registry (CBR) to offer the service, which it started in July 2010.
Today, the majority of private U.S. cord blood banks offer the service. A more in-depth analysis of the rate of market penetration within the U.S. is provided below.
History of Cord Tissue Storage
When an analysis of cord tissue storage was first completed by BioInformant in 2013, only nine companies where offering the service in the United States. These companies are shown in the table below. [Read more…]
Will Cord Blood Banking be the Next Trend in BioBanking?
A biobank is a repository that stores biological samples (usually human) for use in research and medicine. The registration of each sample entering and exiting the system is centrally stored on a computer system that is frequently backed up, and the physical location of each sample is noted to allow efficient location of specimens. Storage of the specimens may range from controlled ambient (room temperature), to +4°C, -20°C, -80°C, and -196°C (liquid or vapor nitrogen, LN2).
Clinical Trials Investigating Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
Currently, there are a number of clinical trials that are investigating the therapeutic potential of mesenchymal stem cells derived from umbilical cord tissue, often called Wharton’s Jelly.
Specific conditions that have been or are now being researched for their potential to be treated with stem cells derived from cord tissue include:
- Cartilage repair
- Diabetes
- Heart disease
- Human Immunodeficiency Virus (HIV)
- Liver disease
- Stroke
- Serious wounds
- Spinal Cord Injury
Clinical trials currently listed as involving the use of cord-tissue derived mesenchymal stem cells include:
- “Intracoronary or Intravenous Infusion Human Wharton’ Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy”
- “Intracoronary Human Wharton’s Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With Acute Myocardial Infarction (AMI)”
To search for more clinical trials using CT-MSCs, head to ClinicalTrials.gov and search for the following terms:
- “Wharton’s Jelly” AND “Mesenchymal Stem Cell”
- “Wharton’s Jelly” AND “Mesenchymal Stem Cells”
- “Umbilical Cord Tissue” AND “Mesenchymal Stem Cell”
- “Umbilical Cord Tissue” AND “Mesenchymal Stem Cells”
ClinicalTrials.gov is website maintained by the U.S. National Institutes of Health (NIH) that is a “registry and results database of publicly and privately supported clinical studies of human participants from around the world.” While an excellent resource, it does not include all clinical trials worldwide, including some which may be listed on international registries.
These searches will capture clinical trials that use varied vocabulary, as well as both singular and plural descriptions of the cell type. Other searches may be effective as well.
Neonatal Sources of Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) can also be derived from other tissue sources besides the newborn umbilical cord.
Specifically, MSCs can be derived from adult sources that include adipose tissue, peripheral blood, and bone marrow, as well as from neonatal tissues that include parts of the placenta and umbilical cord, as explored in the image below. This is significant because pre-clinical and clinical advances with the use of MSCs derived from other sources than cord tissue will create a greater willingness to explore medical applications for cord tissue-derived MSCs.
IMAGE. SOURCES OF MESENCHYMAL STEM CELLS
About Us
BioInformant is the first and only market research firm to specialize in the stem cell industry. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine.
Trends, Influencers, and Leaders in Stem Cells and Cord Blood
We’ve posted new content about stem cells and cord blood that I’m excited to share it with you. Let me know what you think!
Do You Know the Top 5 iPS Cell Influencers (Right Now)?
This article considers five of the most influential people operating within the iPS cell marketplace right now. These individuals are renowned industry experts, innovative thought leaders, and of course, highly-sought after speakers, advisers, and board members. Their individual opinions on iPS cell topics can substantially alter public perception…
*Ocata Therapeutics also covered this iPS cell article in an October 3rd press release. Check it out.
CDI, a FUJIFILM company, Announces Launch of World’s Largest Public Stem Cell Bank
On September 1st, Cellular Dynamics International, a FUJIFILM company, announced news that reverberated throughout the stem cell community. The company launched the world’s largest publicly available stem cell bank, the California Institute for Regenerative Medicine (CIRM) hPSC Repository, and the availability of the first 300 iPS cell lines. [Read more…]
- « Previous Page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- …
- 63
- Next Page »